Dernières nouvelles pour Captivision (NASDAQ:CAPT) Stock

Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03091238/Harbour-900x600-1.png" alt="" class="wp-image-15293" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03091238/Harbour-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03091238/Harbour-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03091238/Harbour-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The biotech has agreed to sell rights to one of its cancer drugs under development for up to $670 million, adding more fuel to its share price rebound this year
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>The Chinese drug developer is on a mission to partner with big names in global pharma, having scored 17 licensing-out deals to date</li>
<li>But without any revenue from commercialized products, its earnings are prone to volatility&nbsp;</li>
</ul>
China's HBM Holdings Ltd. (2142.HK) is building a reputation for itself as the ultimate biopharma partner.
The developer of antibody-based therapies has turned partnership deals into an active business model by licensing its discoveries to global names in the pharmaceutical industry. The company's list of strategic partners grew even longer on Monday when it announced a pact with Japan's&nbsp;Otsuka Pharmaceutical Co. Ltd.&nbsp;(4578.T) on a cancer immunotherapy drug.
In an&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0623/2025062300047.pdf">agreement</a>&nbsp;worth up to $670 million,&nbsp; the Japanese partner gained rights to develop, produce and sell the HBM antibody therapy in markets outside of greater China. The candidate drug, HBM7020, is designed to lock onto two target proteins, BCMA and CD3, to identify and destroy cancer cells.
HBM, which acts as the holding company for Harbour Biomed, stands to gain $47 million in upfront and near-term payments, with further income of up to $623 million linked to development and commercial milestones, as well as royalties on future sales.
The experimental drug in question, which is designed to spur T-cells to destroy malignant B-cells, was approved for Phase One clinical trials in China in 2023. &nbsp;A bispecific antibody targeting the same antigens as HBM7020 but made by Johnson &amp; Johnson has been cleared for treating multiple myeloma, a type of blood cancer.
The link-up with Otsuka takes HBM's tally of licensing-out deals to 17, according to Pharmcube, a provider of pharmaceutical data and analysis. In the first half of 2025 alone, HBM entered into six agreements involving licensing or NewCo transactions, in which drugs under development are spun off into independent firms.
In particular, its ties with pharma giant&nbsp;AstraZeneca&nbsp;(AZN.US) are growing ever tighter. HBM signed a collaboration agreement worth up to $4.58 billion with AstraZeneca (AZN.US) in March to jointly develop multispecific antibodies for autoimmune diseases, cancer and other conditions. The Anglo-Swedish multinational also gained rights to license two preclinical projects and the option to identify additional targets in future. In return, the Chinese biotech got $175 million up front and in near-term payments, as well as option-related fees and up to $4.4 billion in development and commercial milestone payments, plus a share of future sales.
It was the third such collaboration between HBM and AstraZeneca. Back in 2022, HBM licensed out another bispecific antibody to AstraZeneca, CLDN18.2xCD3, for $350 million. Two years later a preclinical monoclonal antibody project from Nona Biosciences, a wholly owned HBM subsidiary, was signed over for more than $600 million. The partners have become more closely entwined with the latest deal, &nbsp;as AstraZeneca subscribed for 9.15% of newly issued HBM shares for $105 million and agreed to set up a joint innovation center in Beijing.
The keen interest from Big Pharma has also excited the stock market. After the Otsuka deal was announced, HBM's share price jumped 12.32% in a single day. Buoyed by a rebound in the biopharma sector, HBM's stock soared 350% in the first half of this year, far outpacing a 58% gain in the Hang Seng Innovative Drug Index.
<h4 class="wp-block-heading">Volatile earnings</h4>
However, that surge comes off a low base. When the biopharma sector was struggling through a downturn, HBM was forced to divest assets and pare back its research projects. &nbsp;Facing persistent losses and financing difficulties, the company transferred its core product, batoclimab, to a subsidiary of&nbsp;CSPC Pharmaceutical Group&nbsp;(1093.HK) in 2022, and halted Phase Three trials for another key asset. The company also sold its Suzhou manufacturing base to WuXi Vaccines, a subsidiary of&nbsp;WuXi Biologics&nbsp;(2269.HK), incurring a loss of 61.93 million yuan ($8.7 million).
In its business reset, HBM established a wholly owned subsidiary, Nona Biosciences, in late 2022 to offer drug research services based on its fully human antibody transgenic mice platform and its in-house bispecific immune cell engager platform. Meanwhile, another subsidiary, Harbour Medical, handles global clinical development of HBM's own drug discoveries.
The twin-engine approach allows HBM to focus resources on its own research projects, emulating a business model used by U.S. innovative drug firm&nbsp;Regeneron&nbsp;(REGN.US).
HBM founder and CEO Wang Jinsong has frequently drawn parallels between the two companies in media interviews, citing the partnership with AstraZeneca as a key step in transforming into a world-class company like Regeneron.
The Chinese drug developer turned a second straight annual profit in 2024, but revenues fell 57% to $38.10 million and net profit plunged 88% to $2.78 million from the previous year. Without any product income, HBM relies heavily on fees from partnership deals, making its earnings volatile.
Its price-to-earnings (P/E) ratio stands at a lofty 325 times, many multiples more than Regeneron's 13 times. The headline deals with pharma giants may offer a short-term fix, but sustained success will hinge on continued innovation and proven results from the licensed-out assets. Investors should keep in mind the inherent risks from a lack of commercialized products.

Asia

Health Care

Opinion

HBM Notches Up Another Mega Deal But Is The Model Sustainable?

Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) will release earnings results for the second quarter, before the opening <a href="https://www.benzinga.com/quote/fast/earnings">bell on Monday, July 14.</a>
Analysts expect the Andover, Massachusetts-based company to report quarterly earnings at 28 cents per share, up from 25 cents per share in the year-ago period. Fastenal projects to report quarterly revenue at $2.07 billion, compared to $1.92 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 23, Fastenal announced a two-for-one stock split.
Fastenal shares fell 0.4% to close at $42.68 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/fast/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Morgan Stanley analyst Chris Snyder maintained an Equal-Weight rating and raised the price target from $38 to $40 on May 23, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Stephens &amp; Co. analyst Tommy Moll maintained an Equal-Weight rating and increased the price target from $75 to $80 on April 15, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Baird analyst David Manthey maintained a Neutral rating and raised the price target from $80 to $86 on April 14, 2025. This analyst has an accuracy rate of 77%.</li>
<li>William Blair analyst Ryan Merkel upgraded the stock from Market Perform to Outperform on March 10, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Stifel analyst Brian Butler maintained a Hold rating and cut the price target from $86 to $82 on Jan. 21, 2025. This analyst has an accuracy rate of 63%.</li>
</ul>
Considering buying FAST stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/FAST/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="567" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03041852/image-35-1024x567.png" alt="" class="wp-image-971602" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03041852/image-35-1024x567.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03041852/image-35-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03041852/image-35-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03041852/image-35.png 1146w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

FAST

Fastenal Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

"I still feel responsibility," former Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) design chief&nbsp; Jony Ive told the Financial Times in an <a href="https://www.ft.com/content/7f0a45b0-a3cc-4e1c-be71-1b7b42958d4d">interview</a> earlier this month. OpenAI announced in May it would acquire his hardware startup for $6.4 billion to develop an AI device aimed at addressing the negative effects of smartphones.&nbsp;
The Apple legend added that "humanity deserves better," promising a gadget that counters screen addiction and anxiety while reviving Silicon Valley's original sense of mission.
<h2 class="wp-block-heading">OpenAI Bets On Hardware</h2>
OpenAI Chief Executive Officer Sam Altman announced on May 21 an all-stock deal to buy Ive's year-old startup io Products for about $6.5 billion, elevating the designer to group creative director.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
</ul>
The transaction would fold Ive's 15-person LoveFrom industrial-design team into OpenAI's San Francisco campus, where engineers plan to fuse large-language-model software with custom silicon for natural voice dialogue. However, the agreement may be in limbo.
A trademark lawsuit filed by a separate startup called iyO has prompted a federal judge to temporarily bar OpenAI from marketing the product under the "io" name. In response, OpenAI CEO Sam Altman <a href="https://x.com/sama/status/1937606794362388674">posted </a>screenshots of email exchanges with iyO founder Jason Rugolo, showing that Rugolo had first approached him about an acquisition. Altman declined, citing a competing product, and called the lawsuit "silly, disappointing and wrong."
A now-pulled 9-minute promotional <a href="https://www.youtube.com/watch?v=rDNyFN_eMec">video</a>—removed after a trademark lawsuit—showed Altman calling their prototype "the coolest piece of technology the world will have ever seen.&#8221;
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation.&nbsp;</a>
<h2 class="wp-block-heading">Prototype Leaves Screens Behind</h2>
TF International Securities analyst Ming-Chi Kuo expects the screen-free device to resemble a neck-worn iPod Shuffle with microphones and cameras that read a user's surroundings,<a href="https://www.macrumors.com/2025/05/22/ming-chi-kuo-on-openai-device-design/"> </a>according to her May <a href="https://x.com/mingchikuo/status/1925543472993321066">X post</a>. Altman also told employees the unit would be "unobtrusive" and "fully aware" of a user's surroundings, designed to sit on a desk or in a pocket and function without a traditional screen, according to <a href="https://www.wsj.com/tech/ai/what-sam-altman-told-openai-about-the-secret-device-hes-making-with-jony-ive-f1384005?mod=rss_Technology">The Wall Street Journal</a>.
<h2 class="wp-block-heading">Mental Health Signals Urgency</h2>
"Many of us would say we have an uneasy relationship with technology at the moment… While some of the less positive consequences were unintentional, I still feel responsibility… The manifestation of that is a determination to try and be useful," Ive told the <a href="https://www.ft.com/content/7f0a45b0-a3cc-4e1c-be71-1b7b42958d4d">FT</a>.
Public-health data amplify the stakes: 11% of U.S. children ages 3–17 have diagnosed anxiety, according to recent <a href="https://www.cdc.gov/children-mental-health/data-research/index.html">Centers for Disease Control and Prevention</a> statistics. A survey released in April by the<a href="https://www.apa.org/monitor/2025/2025-04-05-monitor.pdf"> American Psychological Association</a> found only 58.5% of teens say they routinely receive needed emotional support. A separate<a href="https://www.pewresearch.org/internet/2025/04/22/teens-social-media-and-mental-health/"> Pew Research Center report</a> shows that 34% of teen girls feel social media makes them worse about their lives.
Philanthropist Laurene Powell Jobs echoed those concerns during the same FT interview, warning that technology's "dark uses" have sent youth mental-health trends "sideways."
See Also: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Become an Investor in This $41.3M Clean Energy Brand Today</a>
<h2 class="wp-block-heading">Funding And Release Window</h2>
OpenAI's war chest has swelled with ChatGPT demand. A spokesperson for OpenAI <a href="https://www.cnbc.com/2025/06/09/openai-hits-10-billion-in-annualized-revenue-fueled-by-chatgpt-growth.html">told CNBC</a> that its annual recurring revenue recently climbed to $10 billion, up from approximately $5.5 billion in 2024. This month the <a href="https://www.defense.gov/News/Contracts/Contract/Article/4218062//">Pentagon awarded</a> the firm a $200 million contract to prototype AI tools.&nbsp;
Whether this $6.4 billion vision redefines the future or simply begins to mend it, one thing is clear: Ive is back—this time, to design technology with humanity at its heart.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

AAPL

'I Still Feel Responsibility,' Says Ex-Apple Executive Sir Jony Ive, Pledging to Fix Tech's Harms With $6.4 Billion AI Device

States are accusing the federal government of breaching long-standing laws protecting Medicaid recipients&#8217; private health data by secretly sharing it with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">federal immigration authorities</a>.
California Attorney General Rob Bonta recently filed a lawsuit on the part of a multistate coalition challenging the U.S. Department of Health and Human Services' (HHS) decision to provide &#8220;unfettered access to individual personal health data to the Department of Homeland Security (DHS),&#8221; arguing that it violates federal law, &#8220;threatens to erode trust in the healthcare system, and deters vulnerable populations from seeking care.&#8221;
For over 70 years, federal law has treated Medicaid beneficiaries' personal and medical information as confidential, to be shared only in limited circumstances that support public health or the integrity of the program.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/07/46219622/trump-administrations-health-agency-overstepped-authority-reorganization-unlawful-court" target="_blank" rel="noreferrer noopener">Trump Administration&#8217;s Health Agency Overstepped Authority, Reorganization Unlawful: Court</a>
However, in June 2025, this policy was upended when the Centers for Medicare &amp; Medicaid Services (CMS) under the HHS allegedly transferred sensitive health data from states such as California, Illinois and Washington to the Department of Homeland Security without notifying the public or following proper procedures.
The states <a href="https://oag.ca.gov/system/files/attachments/press-docs/CA%20v.%20HHS%2C%20Complaint%207.1.25.pdf" target="_blank" rel="noreferrer noopener">argue</a> that this mass transfer of health data occurred without beneficiaries' consent and violated multiple federal statutes, including the Administrative Procedure Act.
They further claim this was done under the Trump administration without proper justification or legal authority, undermining the protections Congress established for Medicaid data.
HHS has defended its actions by stating that data sharing helps ensure that Medicaid benefits are only for eligible individuals. However, states contend this rationale is misleading.
Congress has already authorized emergency Medicaid for all U.S. residents, regardless of immigration status; states routinely verify eligibility using federally approved systems. They insist there is no precedent or legal basis for the type of cross-agency data sharing CMS is now enabling.
Adding to the concern is the broader context. Reports suggest the Department of Government Efficiency (DOGE) is compiling a vast, searchable database of Americans&#8217; personal information—including tax and Social Security data—to aid in immigration enforcement.
Technology company Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) is reportedly assisting in this effort.
Critics warn that centralizing such sensitive data dramatically increases the risk of misuse, even with the best intentions.
The states involved in the lawsuit say they are taking action to safeguard their Medicaid programs and shield their residents from harm.
They warn that such data sharing could prompt fear among immigrants, causing them to opt out of Medicaid enrollment—even when they are eligible—leading to a loss of federal funding, a strain on state safety net hospitals, and adverse public health outcomes.
States are asking the court to issue immediate relief to stop the unauthorized sharing and uphold the longstanding principles of the state-federal Medicaid partnership.
"The Trump Administration has upended longstanding privacy protections with its decision to illegally share sensitive, personal health data with ICE. In doing so, it has created a culture of fear that will lead to fewer people seeking vital emergency medical care," <a href="http://oag.ca.gov/news/press-releases/attorney-general-bonta-sues-trump-administration-illegally-sharing-californians'" target="_blank" rel="noreferrer noopener">said</a> AG Bonta in a statement on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46242838/anthony-scaramucci-predicts-bitcoin-treasury-frenzy-will-fade" target="_blank" rel="noreferrer noopener">Anthony Scaramucci Predicts Bitcoin Treasury Frenzy &#8216;Will Fade&#8217;</a></li>
</ul>
Photo: Shutterstock

Government

Legal

General

PLTR

Palantir Reportedly Assisting Trump Administration's DOGE To Compile Americans' Personal Data

Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) has outperformed the market over the past 15 years by 14.23% on an annualized basis producing an average annual return of 26.65%. Currently, Super Micro Computer has a market capitalization of $29.41 billion. 
Buying $1000 In SMCI: If an investor had bought $1000 of SMCI stock 15 years ago, it would be worth $36,599.93 today based on a price of $49.27 for SMCI at the time of writing.
<h3>Super Micro Computer's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751553957_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SMCI

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher following upbeat June jobs data figures. Nonfarm payrolls beat estimates while the unemployment rate and initial jobless claims came in below expectations.

RBC Capital analyst Arun Viswanathan maintains Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) with a Outperform and raises the price target from $88 to $92.

RBC Capital Maintains Outperform on Westlake, Raises Price Target to $92

<a href="https://www.axios.com/2025/07/03/iran-nuclear-talks-witkoff-meeting">https://www.axios.com/2025/07/03/iran-nuclear-talks-witkoff-meeting</a>

Macro Notification

Politics

'Trump's envoy plans nuclear talks with Iran in Oslo next week'- Axios

RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) with a Outperform and raises the price target from $14 to $15.

RBC Capital Maintains Outperform on Chemours, Raises Price Target to $15

RBC Capital analyst Arun Viswanathan maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Sector Perform and lowers the price target from $25 to $23.

RBC Capital Maintains Sector Perform on Olin, Lowers Price Target to $23

U.S. stocks were higher, with the Dow Jones index gaining over 200 points on Thursday.
Shares of Olo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>) rose sharply during Thursday's session after the company announced that it entered into a definitive agreement to be <a href="https://www.benzinga.com/quote/OLO">acquired by Thoma Bravo</a>.
Olo shares jumped 13.5% to $10.11 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares jumped 48.8% to $15.41.</li>
<li>Bitmine Immersion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) gained 36% to $80.00.</li>
<li>Concorde International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGL#NASDAQ">CIGL</a>) gained 21.7% to $22.68.</li>
<li>Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) jumped 18% to $17.70 after activist investor Starboard Value acquired a 9% stake in the company.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) rose 16.4% to $23.71. DeFi Development purchased 17,760 SOL.</li>
<li>Aebi Schmidt Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEBI#NASDAQ">AEBI</a>) gained 16.4% to $13.01 after making its Nasdaq debut following its merger with the Shyft Group.</li>
<li>So-Young International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SY#NASDAQ">SY</a>) gained 15.6% to $3.85. So-Young regained compliance with Nasdaq Minimum Bid Price Requirement.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) jumped 13% to $10.16.</li>
<li>Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) gained 11.88% to $150.98 after it was announced the company is set to join the S&amp;P 500.</li>
<li>TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) rose 10.3% to $7.03.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) rose 8.6% to $45.85.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) jumped 8.4% to $33.39.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) gained 8.4% to $184.79.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) rose 5.6% to $2.1650 after the company reported second-quarter production of 3,863 vehicles and deliveries of 3,309.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Movers

AEBI

BMNR

CIGL

DDOG

DFDV

FSLR

LCID

TRIP

Olo, Tripadvisor, Aebi Schmidt Holding And Other Big Stocks Moving Higher On Thursday

RBC Capital analyst Arun Viswanathan maintains LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) with a Sector Perform and raises the price target from $61 to $64.

RBC Capital Maintains Sector Perform on LyondellBasell Industries, Raises Price Target to $64

RBC Capital analyst Arun Viswanathan maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Sector Perform and raises the price target from $53 to $63.

RBC Capital Maintains Sector Perform on Celanese, Raises Price Target to $63

The natural gas market continues to navigate a complex mix of seasonal demand patterns, weather volatility and fluctuating supply and demand. To better understand where the natural gas market might be heading this summer, let's take a look at the latest trends in prices, storage, and weather forecasts.
<h2 class="wp-block-heading"> Current prices vs. price spread 10 days before expiry by month since 2010</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="591" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213527/image-2-2-1024x591.png" alt="" class="wp-image-15254" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213527/image-2-2-1024x591.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213527/image-2-2-300x173.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213527/image-2-2-768x444.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213527/image-2-2.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The graph was constructed by the author's team based on an analysis of data from Bloomberg and EIA.</figcaption></figure>
Conclusions: The 2025 summer natural gas contracts are still trading above the median expiration price, but remain within the interquartile range. Winter 2026 contracts declined relative to the previous week but remain higher than 2025, similar dynamics can be seen in 2027. The market is slowly but still starting to stabilize. 
<h2 class="wp-block-heading">Forward curve vs. 2020-2024</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="637" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213536/image-3-1024x637.png" alt="" class="wp-image-15255" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213536/image-3-1024x637.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213536/image-3-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213536/image-3-768x477.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213536/image-3.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The graph was constructed by the author's team based on an analysis of data from Bloomberg and EIA.</figcaption></figure>
Conclusions: A strong upward skew on the curve persists through 2025 despite last week&#8217;s price decline. The shape of the curve after 2027 is still more stable, and the decline in outright contract prices hasn&#8217;t changed it. It is still in a price range close to the corresponding 2023-2024 curves for the same period of the year. 
<h2 class="wp-block-heading">Current inventory and forecast for next week compared to 2019-2024</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="659" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213545/image-2-3-1024x659.png" alt="" class="wp-image-15256" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213545/image-2-3-1024x659.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213545/image-2-3-300x193.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213545/image-2-3-768x494.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213545/image-2-3.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The graph was constructed by the author's team based on an analysis of data from Bloomberg and EIA.</figcaption></figure>
Conclusions: For week 26 (June 21-27) we expect a 45 BCF increase in storage. The filling level will be above the median for the previous 5 years. In spite of falling pumping rates, if the current supply and demand situation persists, the peak level of 2024 is possible. The weather in the second half of summer remains a constraint.
<h2 class="wp-block-heading">Weekly HDD+CDD total from current NOAA data and forecast for the next two weeks comparing 1994-2024</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="659" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213554/image-4-1024x659.png" alt="" class="wp-image-15257" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213554/image-4-1024x659.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213554/image-4-300x193.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213554/image-4-768x494.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213554/image-4.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The graph was constructed by the author's team based on an analysis of data from Bloomberg and EIA.</figcaption></figure>
Conclusions: HDD+CDD values in the first half of June were below the median. Week 27 (June 30-July06) is expected to be still hot relative to the last 30 years. Forecast values for week 28 are on the upper quantile.
Explanation of the chart: in candlesticks quantiles for 30 years from 1994 to 2024. Red dots 2024, green 2025, blue prediction 2025 
<h2 class="wp-block-heading">Weekly HDD+CDD total from current NOAA data and forecast for the next two weeks compared to 1994-2024 by region</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="659" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213602/image-2-4-1024x659.png" alt="" class="wp-image-15258" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213602/image-2-4-1024x659.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213602/image-2-4-300x193.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213602/image-2-4-768x494.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213602/image-2-4.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The graph was constructed by the author's team based on an analysis of data from Bloomberg and EIA.</figcaption></figure>
Conclusions: If we take a look by regions, we see forecast values for the current and next week above average in almost all regions.
Change in monthly weather averages for 10 years from 1990 to 2024
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="467" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213608/image-5-1024x467.png" alt="" class="wp-image-15259" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213608/image-5-1024x467.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213608/image-5-300x137.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213608/image-5-768x350.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213608/image-5.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The graph was constructed by the author's team based on an analysis of data from Bloomberg and EIA.</figcaption></figure>
Conclusions: July has gotten 20 HDD+CDD units hotter over the past 30 years 
Weekly cumulative supply/demand difference compared to 2014-2024
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="610" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213618/image-6-1024x610.png" alt="" class="wp-image-15260" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213618/image-6-1024x610.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213618/image-6-300x179.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213618/image-6-768x458.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213618/image-6.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The graph was constructed by the author's team based on an analysis of data from Bloomberg and EIA.</figcaption></figure>
Conclusions: The April-June 2025 supply/demand balance data is well below the 10-year median due to low temperatures in the first half of summer. The last two weeks have seen a trend reversal towards a higher balance above the historical median. At the same time, due to production growth over the last week, we are watching whether the increased demand from consumption will be compensated by production growth or not.
<h2 class="wp-block-heading">Percentage change in Spot and nearby futures price relative to the beginning of the year for 2010-2025 by month</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="391" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213626/image-2-5-1024x391.png" alt="" class="wp-image-15261" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213626/image-2-5-1024x391.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213626/image-2-5-300x115.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213626/image-2-5-768x293.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213626/image-2-5.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The graph was constructed by the author's team based on an analysis of data from Bloomberg and EIA.</figcaption></figure>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="349" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213632/image-7-1024x349.png" alt="" class="wp-image-15262" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213632/image-7-1024x349.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213632/image-7-300x102.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213632/image-7-768x262.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/02213632/image-7.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The graph was constructed by the author's team based on an analysis of data from Bloomberg and EIA.</figcaption></figure>
Conclusions: Based on 15 years of statistics, spot and near-term futures are trading with minimal divergence in July.

Commodities

Natural Gas Weekly Update: Contracts, Storage, and Weather Risks

EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) is currently in Phase 9 of its 18-phase Adhishthana Cycle on the monthly chart. Let's break down why the stock has been rallying and what the structure tells us under the lens of the Adhishthana framework.
<h3 class="wp-block-heading">Why Did EMCOR Start Rallying in September 2023?</h3>
If you've been following my recent articles, you'd know that according to the Adhishthana Principles, a stock forms its Cakra, a bullish channel with an arc, from Phase 4 through Phase 8. The breakout for this Cakra typically occurs in Phase 9, which is when the stock begins to show its "supreme nature."
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1144" height="1026" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03102735/EME-Monthly-Cakra-Breakout-Adhishthana.png" alt="Fig.1 EMCOR Monthly Chart (Source: Adhishthana.com Reports)" class="wp-image-15297" style="width:659px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03102735/EME-Monthly-Cakra-Breakout-Adhishthana.png 1144w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03102735/EME-Monthly-Cakra-Breakout-Adhishthana-300x269.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03102735/EME-Monthly-Cakra-Breakout-Adhishthana-1024x918.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03102735/EME-Monthly-Cakra-Breakout-Adhishthana-768x689.png 768w" sizes="(max-width: 1144px) 100vw, 1144px" /><figcaption class="wp-element-caption">Fig.1 EMCOR Monthly Chart (Source: Adhishthana.com Reports)</figcaption></figure>
That's exactly what EMCOR stock did. After completing its Cakra in Phase 8, the stock broke out of it in September 2023. Since then, it's rallied ~188%, marking the ascent of its Adhishthana Himalayan Formation.
<h3 class="wp-block-heading">Weekly Chart: Phase 4 and the Yajya Arc</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="522" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03102654/EME-Stock-Weekly-Adhishthana-.png" alt="Fig.2 EMCOR Weekly Chart (Source: Adhishthana.com Reports)" class="wp-image-15296" style="width:699px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03102654/EME-Stock-Weekly-Adhishthana-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03102654/EME-Stock-Weekly-Adhishthana--300x131.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03102654/EME-Stock-Weekly-Adhishthana--1024x445.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03102654/EME-Stock-Weekly-Adhishthana--768x334.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.2 EMCOR Weekly Chart (Source: Adhishthana.com Reports)</figcaption></figure>
On the weekly chart, EME has just entered Phase 4 after forming a well-defined arc, known as Yajya in Adhishthana terminology. The stock has been closely aligned with the principles so far, most notably, during Phase 2 when it delivered the textbook ‘Rally of Buddhi,' gaining nearly 91%. Currently, being in Phase 4, the stock has entered a no-action period. This phase is expected to run its course until 19 April 2026.
<h3 class="wp-block-heading">Conclusion: Monthly Bullish, Weekly Neutral</h3>
The monthly chart is bullish and still in Phase 9, which ends on 30 June 2026. The breakout has already happened, and the stock is now on the ascent of its Himalayan structure. According to Adhishthana timing principles, the peak could occur somewhere between the 18th and 23rd bars of Phase 10, pointing to a possible top around 2028.
However, because the weekly chart is in Phase 4 (a no-action zone), price action may remain choppy and volatile until April 2026. Despite that, the undertone remains bullish.
<h3 class="wp-block-heading">Investor Outlook</h3>
The long-term structure is intact and still ascending. A reversal isn&#8217;t on the table yet. Long-term holders should stay the course, as more upside is likely once the stock enters Phase 10 on the monthly chart.
Short-term traders or new entrants should be cautious. With the weekly chart in Phase 4 until April 2026, any new positions now may face volatility. A cleaner entry opportunity could arise post-Phase 4, when a slight pullback occurs, offering a better reward-risk setup.

Equities

Technicals

Signals

EMCOR Stock: What's Fueling The Rally?

RBC Capital analyst Ken Herbert maintains Mercury Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) with a Sector Perform and raises the price target from $50 to $55.

MRCY

RBC Capital Maintains Sector Perform on Mercury Sys, Raises Price Target to $55

HOOD

Robinhood shares are trading lower. It was speculated the stock could have been added to the S&P 500 but Datadog was added instead.

American Strategic Investment Co. Shares Halted

CIBC analyst Stephanie Price reinstates BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Neutral and announces C$33 price target.

Initiation

TSX:BCE

CIBC Reinstates Neutral on BCE, Announces C$33 Price Target

Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has outperformed the market over the past 5 years by 4.31% on an annualized basis producing an average annual return of 19.07%. Currently, Microsoft has a market capitalization of $3.71 trillion. 
Buying $100 In MSFT: If an investor had bought $100 of MSFT stock 5 years ago, it would be worth $236.57 today based on a price of $498.45 for MSFT at the time of writing.
<h3>Microsoft's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751553019_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MSFT

$100 Invested In Microsoft 5 Years Ago Would Be Worth This Much Today

Press Releases

Captivision Reports Half-Year Results for 2024

Captivision Announces Venture at Dream Hollywood Hotel

Captivision Announces Venture with digiLED and Canary Wharf Group

Captivision Completes Major Project in Seoul with Lotte Group

Management

Captivision Appoints John Jureller to Board of Directors

Captivision Appoints Ric Clark to Board of Directors

Captivision Unveils New Corporate Branding, Paving the Way for a Transformative Era of Growth

Captivision Receives Notification from Nasdaq Related to Delayed Annual Report on Form 20-F

Captivision, Inc. Announces Receipt of Staff Determination Letter from Nasdaq

Contracts

Captivision and digiLED Complete Phase One of Landmark LED Installations at Canary Wharf

CAPT

Captivision

Comments

Captivision

Actualités

Dernières nouvelles pour Captivision (NASDAQ:CAPT) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL